PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells

Shijie Xu,1,* Fangbo Cui,2,3,* Dafu Huang,4,* Dinghu Zhang,5 Anqing Zhu,6 Xia Sun,6 Yiming Cao,7 Sheng Ding,7 Yao Wang,7 Eryun Gao,3 Fenglin Zhang3 1Center for Public Health Research, Medical School, Nanjing University, Nanjing, China; 2Department of Oncology, Wannan Medical College, Wuhu, Anhui, C...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Xu S, Cui F, Huang D, Zhang D, Zhu A, Sun X, Cao YM, Ding S, Wang Y, Gao E, Zhang F
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
DOC
Acceso en línea:https://doaj.org/article/8adb6dffae104d9f83111c412d59d0e8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:8adb6dffae104d9f83111c412d59d0e8
record_format dspace
spelling oai:doaj.org-article:8adb6dffae104d9f83111c412d59d0e82021-12-02T00:40:33ZPD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells1178-2013https://doaj.org/article/8adb6dffae104d9f83111c412d59d0e82018-12-01T00:00:00Zhttps://www.dovepress.com/pd-l1-monoclonal-antibody-conjugated-nanoparticles-enhance-drug-delive-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Shijie Xu,1,* Fangbo Cui,2,3,* Dafu Huang,4,* Dinghu Zhang,5 Anqing Zhu,6 Xia Sun,6 Yiming Cao,7 Sheng Ding,7 Yao Wang,7 Eryun Gao,3 Fenglin Zhang3 1Center for Public Health Research, Medical School, Nanjing University, Nanjing, China; 2Department of Oncology, Wannan Medical College, Wuhu, Anhui, China; 3Department of Oncology, The People’s Hospital of Ma Anshan, Ma Anshan, Anhui, China; 4Department of Oncology, Nanjing Lishui People’s Hospital, Zhongda Hospital Lishui Branch, Southeast University, Nanjing, Jiangsu, China; 5Department of Oncology, Tongde Hospital of Zhejiang Province, Hangzhou, China; 6Department of Oncology, The Affliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, Jiangsu, China; 7Department of General Surgery, The People’s Hospital of Ma Anshan, Ma Anshan, Anhui, China *These authors contributed equally to this work Background: Docetaxel (DOC) is widely used as a chemotherapy drug for various tumors, including gastric cancer (GC), but the clinical application of DOC has been limited due to the hydrophobicity of the drug. We aimed to formulate a multifunctional nanoparticle (NP) system to reduce the side effects of the chemotherapy agent, to promote synergistic therapeutic effects, and to achieve targeted delivery of the therapy. Methods: The polyethylene glycol-poly(ε-caprolactone) NPs (PEG-PCL NPs) were prepared by a ring opening copolymerization technique and were then conjugated with a programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb). The effects of the surface coating on particle size, size distribution, zeta potential, drug encapsulation efficiency, loading capacity, and the drug release kinetics were investigated. By using a panel of PD-L1-expressing human GC cell lines and PD-L1-overexpressing cells, we studied cellular uptake, cytotoxic effects, and cellular apoptosis in the presence of PD-L1 mAb-conjugated NPs. Results: The characterization of the structure and biological functions of DOC-PEG-PCL-mAb NPs was investigated in vitro. X-ray photoelectron spectroscopy validated the presence of the PD-L1 mAbs on the NP surface. The cellular uptake analysis showed that the antibody-conjugated NPs achieved significantly higher cellular uptake. The results of an in vitro cytotoxicity experiment on three GC lines further proved the targeting effects of the antibody conjugation. In addition, we found that the DOC-PEG-PCL-mAb NPs induced cell apoptosis and enhanced G2-M arrest in cancer cells, indicating the inhibition of microtubule synthesis. When compared with the control groups, DOC-PEG-PCL-mAb NPs are more effective in inhibiting PD-L1 expression in GC cells. Conclusion: Our results reported here highlight the biological and clinical potential of DOC-PEG-PCL-mAb NPs using PD-L1 mAbs in GC treatment. Keywords: DOC, gastric carcinoma, PD-L1 monoclonal antibody, nanomedicine, drug deliveryXu SCui FHuang DZhang DZhu ASun XCao YMDing SWang YGao EZhang FDove Medical PressarticleDOCGastric carcinomaPD-L1 monoclonal antibodyNanomedicineDrug deliveryMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 17-32 (2018)
institution DOAJ
collection DOAJ
language EN
topic DOC
Gastric carcinoma
PD-L1 monoclonal antibody
Nanomedicine
Drug delivery
Medicine (General)
R5-920
spellingShingle DOC
Gastric carcinoma
PD-L1 monoclonal antibody
Nanomedicine
Drug delivery
Medicine (General)
R5-920
Xu S
Cui F
Huang D
Zhang D
Zhu A
Sun X
Cao YM
Ding S
Wang Y
Gao E
Zhang F
PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells
description Shijie Xu,1,* Fangbo Cui,2,3,* Dafu Huang,4,* Dinghu Zhang,5 Anqing Zhu,6 Xia Sun,6 Yiming Cao,7 Sheng Ding,7 Yao Wang,7 Eryun Gao,3 Fenglin Zhang3 1Center for Public Health Research, Medical School, Nanjing University, Nanjing, China; 2Department of Oncology, Wannan Medical College, Wuhu, Anhui, China; 3Department of Oncology, The People’s Hospital of Ma Anshan, Ma Anshan, Anhui, China; 4Department of Oncology, Nanjing Lishui People’s Hospital, Zhongda Hospital Lishui Branch, Southeast University, Nanjing, Jiangsu, China; 5Department of Oncology, Tongde Hospital of Zhejiang Province, Hangzhou, China; 6Department of Oncology, The Affliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, Jiangsu, China; 7Department of General Surgery, The People’s Hospital of Ma Anshan, Ma Anshan, Anhui, China *These authors contributed equally to this work Background: Docetaxel (DOC) is widely used as a chemotherapy drug for various tumors, including gastric cancer (GC), but the clinical application of DOC has been limited due to the hydrophobicity of the drug. We aimed to formulate a multifunctional nanoparticle (NP) system to reduce the side effects of the chemotherapy agent, to promote synergistic therapeutic effects, and to achieve targeted delivery of the therapy. Methods: The polyethylene glycol-poly(ε-caprolactone) NPs (PEG-PCL NPs) were prepared by a ring opening copolymerization technique and were then conjugated with a programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb). The effects of the surface coating on particle size, size distribution, zeta potential, drug encapsulation efficiency, loading capacity, and the drug release kinetics were investigated. By using a panel of PD-L1-expressing human GC cell lines and PD-L1-overexpressing cells, we studied cellular uptake, cytotoxic effects, and cellular apoptosis in the presence of PD-L1 mAb-conjugated NPs. Results: The characterization of the structure and biological functions of DOC-PEG-PCL-mAb NPs was investigated in vitro. X-ray photoelectron spectroscopy validated the presence of the PD-L1 mAbs on the NP surface. The cellular uptake analysis showed that the antibody-conjugated NPs achieved significantly higher cellular uptake. The results of an in vitro cytotoxicity experiment on three GC lines further proved the targeting effects of the antibody conjugation. In addition, we found that the DOC-PEG-PCL-mAb NPs induced cell apoptosis and enhanced G2-M arrest in cancer cells, indicating the inhibition of microtubule synthesis. When compared with the control groups, DOC-PEG-PCL-mAb NPs are more effective in inhibiting PD-L1 expression in GC cells. Conclusion: Our results reported here highlight the biological and clinical potential of DOC-PEG-PCL-mAb NPs using PD-L1 mAbs in GC treatment. Keywords: DOC, gastric carcinoma, PD-L1 monoclonal antibody, nanomedicine, drug delivery
format article
author Xu S
Cui F
Huang D
Zhang D
Zhu A
Sun X
Cao YM
Ding S
Wang Y
Gao E
Zhang F
author_facet Xu S
Cui F
Huang D
Zhang D
Zhu A
Sun X
Cao YM
Ding S
Wang Y
Gao E
Zhang F
author_sort Xu S
title PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells
title_short PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells
title_full PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells
title_fullStr PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells
title_full_unstemmed PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells
title_sort pd-l1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells
publisher Dove Medical Press
publishDate 2018
url https://doaj.org/article/8adb6dffae104d9f83111c412d59d0e8
work_keys_str_mv AT xus pdl1monoclonalantibodyconjugatednanoparticlesenhancedrugdeliverylevelandchemotherapyefficacyingastriccancercells
AT cuif pdl1monoclonalantibodyconjugatednanoparticlesenhancedrugdeliverylevelandchemotherapyefficacyingastriccancercells
AT huangd pdl1monoclonalantibodyconjugatednanoparticlesenhancedrugdeliverylevelandchemotherapyefficacyingastriccancercells
AT zhangd pdl1monoclonalantibodyconjugatednanoparticlesenhancedrugdeliverylevelandchemotherapyefficacyingastriccancercells
AT zhua pdl1monoclonalantibodyconjugatednanoparticlesenhancedrugdeliverylevelandchemotherapyefficacyingastriccancercells
AT sunx pdl1monoclonalantibodyconjugatednanoparticlesenhancedrugdeliverylevelandchemotherapyefficacyingastriccancercells
AT caoym pdl1monoclonalantibodyconjugatednanoparticlesenhancedrugdeliverylevelandchemotherapyefficacyingastriccancercells
AT dings pdl1monoclonalantibodyconjugatednanoparticlesenhancedrugdeliverylevelandchemotherapyefficacyingastriccancercells
AT wangy pdl1monoclonalantibodyconjugatednanoparticlesenhancedrugdeliverylevelandchemotherapyefficacyingastriccancercells
AT gaoe pdl1monoclonalantibodyconjugatednanoparticlesenhancedrugdeliverylevelandchemotherapyefficacyingastriccancercells
AT zhangf pdl1monoclonalantibodyconjugatednanoparticlesenhancedrugdeliverylevelandchemotherapyefficacyingastriccancercells
_version_ 1718403567874736128